Nurexone Biologic Inc (NRXBF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -5,043 | -3,497 | -2,247 | -922 | -3,639 |
| Depreciation Amortization | 85 | 46 | 28 | 15 | 33 |
| Other Working Capital | -923 | -362 | -410 | -563 | 4 |
| Other Operating Activity | 993 | 660 | 294 | 5 | 661 |
| Operating Cash Flow | $-4,888 | $-3,153 | $-2,335 | $-1,465 | $-2,941 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -649 | -603 | -302 | -241 | -120 |
| Other Investing Activity | -9 | -10 | -10 | 0 | 23 |
| Investing Cash Flow | $-658 | $-613 | $-312 | $-241 | $-97 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 5,837 | 4,344 | 2,934 | 2,919 | N/A |
| Other Financing Activity | 41 | 1,357 | 1,508 | 1,479 | 1,132 |
| Financing Cash Flow | $5,878 | $5,701 | $4,442 | $4,398 | $1,132 |
| Exchange Rate Effect | -173 | 47 | 49 | 22 | -16 |
| Beginning Cash Position | 541 | 541 | 541 | 541 | 2,463 |
| End Cash Position | 700 | 2,523 | 2,385 | 3,255 | 541 |
| Net Cash Flow | $159 | $1,982 | $1,844 | $2,714 | $-1,922 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,888 | -3,153 | -2,335 | -1,465 | -2,941 |
| Capital Expenditure | -649 | -603 | -302 | -241 | -120 |
| Free Cash Flow | -5,537 | -3,756 | -2,637 | -1,706 | -3,061 |